http://orcid.org/0000-0001-5420-279X
References
- International Diabetes Federation. IDF Diabetes Atlas, 7th edition. http://www.diabetesatlas.org/across-the-globe.html. [Last accessed 16 February 2017].
- Zhuo X, Zhang P, Hoerger TJ. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med 2013;45:253-61
- American Diabetes Association. Glycemic targets. Diabetes Care 2017;40(Supp1):S48-S56
- Benhalima K, Standl E, Mathieu C. The importance of glycemic control: how low should we go with HbA1c? Start early, go safe, go low. J Diabetes Complications 2011;25:202-7
- Eldor R, Raz I. The individualized target HbA1c: a new method for improving macrovascular risk and glycemia without hypoglycemia and weight gain. Rev Diabet Stud 2009;6:6-12
- Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93
- Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91
- Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016;59:2298-307
- Webb DR, Khunti K, Gray LJ, et al. Intensive multifactorial intervention improves modelled coronary heart disease risk in screen-detected Type 2 diabetes mellitus: a cluster randomized controlled trial. Diabet Med 2012;29:531-40
- Sandbæk A, Griffin SJ, Sharp SJ, et al. Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomized controlled trial: the ADDITION-Europe Study. Diabetes Care 2014;37:2015-23
- American Diabetes Association. Obesity management for the treatment of type 2 diabetes. Diabetes Care 2017;40(Supp1):S57-S63
- American Diabetes Association. Pharmacologic approaches to glycemic treatment. Diabetes Care 2017;40(Supp1):S64-S74
- American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care 2017;40(Supp1):S75-S87
- Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 2011;34(Suppl2):S279-S84
- Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context 2015;4:212283
- Nauk M, Rizzo M, Johson A, et al. Once-daily liraglutide versus lixisenatide as add-on to metformin in type 2 diabetes: a 26-week randomized controlled clinical trial. Diabetes Care 2016;39:1501-9
- Langer J, Hunt B, Valentine WJ. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. J Manag Care Pharm 2013;19:237-46
- Skovgaard R, Jon Ploug U, Hunt B, et al. Evaluating the cost of bringing people with type 2 diabetes mellitus to multiple targets of treatment in Canada. Clin Ther 2015;37:1677-88